急性照護症候群檢測市場－全球產業規模、佔有率、趨勢、機會和預測，按疾病類型、目標、樣本類型、最終用戶、地區和競爭細分，2020 年至 2030 年

2024年全球急性護理症候群檢測市場價值31.2億美元，預計預測期內將達到46.7億美元，到2030年的複合年成長率為6.91%。急性護理綜合症檢測市場是一種在醫療保健機構（尤其是急診和急性護理機構）中使用的診斷方法，用於快速識別和診斷患者急性症狀或病症的病因。這種方法涉及同時檢測可能導致患者症狀的多種病原體（例如病毒、細菌和其他微生物）。其目標是快速縮小潛在病因範圍並指導適當的治療決策。當患者出現的症狀可能由多種傳染源引起時，急性護理綜合症檢測尤其重要。這種檢測策略使醫療保健提供者能夠及時做出明智的患者護理、隔離措施和治療方案決策。它在疾病爆發或大流行期間尤其有價值，因為它可以幫助醫療保健系統有效地管理和應對大量具有相似症狀的患者。然而，急性護理症候群檢測中使用的特定檢測類型可能包括分子檢測（如聚合酶鍊式反應或PCR檢測）、快速抗原檢測、血清學檢測（尋找抗體）和其他診斷方法。檢測方法的選擇取決於疑似病原體和臨床情況。

市場概覽
預測期	2026-2030
2024年市場規模	31.2億美元
2030年市場規模	46.7億美元
2025-2030 年複合年成長率	6.91%
成長最快的領域	呼吸系統疾病
最大的市場	亞太

關鍵市場促進因素

傳染病疫情增加

主要市場挑戰

來自其他診斷測試的競爭

主要市場趨勢

即時檢驗（POCT）的興起

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球急性照護症候群檢測市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依疾病類型（呼吸系統疾病、胃腸疾病、泌尿生殖系統疾病、熱帶疾病、其他）
  • 依目標（細菌、病毒、真菌、寄生蟲）
  • 依樣本類型（血液、尿液、體液、糞便、拭子、其他）
  • 按最終使用者（醫院、臨床和診斷實驗室、研究和學術機構、其他）
  • 按公司分類（2024）
  • 按地區
• 市場地圖

第6章：北美急性照護症候群檢測市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 美國
  • 墨西哥
  • 加拿大

第7章：歐洲急性護理症候群檢測市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 法國
  • 德國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太急性照護症候群檢測市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 韓國
  • 日本
  • 澳洲

第9章：南美洲急性照護症候群檢測市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第10章：中東和非洲急性護理症候群檢測市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 最新動態
• 產品發布
• 併購

第 13 章： 大環境分析

第 14 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 15 章：競爭格局

• Abbott Laboratories
• Becton, Dickinson and Company
• Biocartis NV
• bioMerieux SA (BioFire Diagnostics)
• Danaher Corporation (Cepheid, Inc.)
• DiaSorin SpA (Luminex Corporation)
• Eurofins Scientific (Eurofins Viracor)
• Hologic Inc.
• Laboratory Corporation of America Holdings.
• QIAGEN NV

第 16 章：策略建議

第17章調查會社について,免責事項

Global Acute Care Syndromic Testing Market was valued at USD 3.12 billion in 2024 and is expected to reach USD 4.67 billion in the forecast period with a CAGR of 6.91% through 2030. Acute Care Syndromic Testing Markets are diagnostic approach used in healthcare settings, particularly in emergency departments and acute care facilities, to rapidly identify and diagnose the cause of acute symptoms or conditions in patients. This approach involves the simultaneous testing of multiple pathogens (such as viruses, bacteria, and other microorganisms) that could be responsible for a patient's symptoms. The goal is to quickly narrow down the potential causes and guide appropriate treatment decisions. Acute care syndromic testing is especially important in situations where patients present with symptoms that could be attributed to various infectious agents. This testing strategy allows healthcare providers to make timely and informed decisions regarding patient care, isolation measures, and treatment options. It can be particularly valuable during disease outbreaks or pandemics, as it helps healthcare systems efficiently manage and respond to a large number of patients with similar symptoms. However, The specific types of tests used in acute care syndromic testing may include molecular assays (like polymerase chain reaction or PCR tests), rapid antigen tests, serological tests (looking for antibodies), and other diagnostic methods. The choice of tests depends on the suspected pathogens and the clinical context.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 3.12 Billion
Market Size 2030	USD 4.67 Billion
CAGR 2025-2030	6.91%
Fastest Growing Segment	Respiratory Disease
Largest Market	Asia-Pacific

Key Market Drivers

Rise in Infectious Disease Outbreaks

The rise in infectious disease outbreaks has a significant impact on driving the growth of the global acute care syndromic testing market. Infectious disease outbreaks create a heightened demand for rapid and accurate diagnostic solutions, and acute care syndromic testing addresses this need. Influenza is the most common infectious disease in the world, but some diseases are more prevalent than others. In the United States alone, about 1 in every 5 people gets the flu every year, but only about 300 people get prion disease each year. Acute care syndromic testing enables healthcare providers to quickly identify the pathogens responsible for the outbreak. Rapid diagnosis allows for early detection and timely implementation of containment measures, such as isolating infected individuals and implementing infection control protocols. During an outbreak, healthcare facilities experience an influx of patients with similar symptoms. Acute care syndromic testing streamlines patient management by providing a comprehensive assessment of the potential pathogens causing the outbreak, allowing for appropriate treatment and care planning. Identifying the causative agent of an outbreak promptly helps limit its spread within the community and healthcare settings. Acute care syndromic testing assists in identifying carriers, isolating cases, and preventing further transmission. Different infectious agents may require specific treatments. Acute care syndromic testing aids in tailoring treatment plans by providing information about the pathogens involved and their susceptibility to different therapies, which can lead to more effective patient outcomes. Outbreaks often strain healthcare resources. Acute care syndromic testing optimizes resource allocation by quickly identifying cases that require immediate attention and enabling efficient use of medical supplies, personnel, and facilities. Infectious disease outbreaks have highlighted the importance of global health security. Acute care syndromic testing is a critical tool in enhancing preparedness and response capabilities, ensuring a rapid and effective response to emerging threats.

The increasing frequency of global outbreaks such as COVID-19, Zika, Ebola, and emerging influenza strains has underscored the urgent need for robust syndromic testing platforms that can detect a wide array of pathogens within hours. This rapid detection is critical not only for individual patient care but also for public health surveillance, enabling governments and health agencies to monitor the spread of infectious diseases in real time. Acute care syndromic testing systems integrate automation, multiplexing, and high-throughput capabilities, allowing labs and emergency departments to manage high patient volumes while ensuring diagnostic accuracy. These innovations have made syndromic testing essential during crisis scenarios where timely responses can mitigate large-scale outbreaks.

According to the World Health Organization (WHO), infectious diseases cause over 17 million deaths annually, with respiratory infections alone accounting for around 4 million of these cases. This staggering burden emphasizes the need for faster diagnostic interventions in acute settings. The global interconnectedness of travel and trade has increased the speed at which pathogens can cross borders, making syndromic testing a critical first line of defense in hospitals and clinics worldwide. As healthcare systems continue to evolve to handle pandemics and antibiotic resistance, the integration of acute care syndromic testing into emergency protocols is likely to become standard practice, driving sustained growth in the market.

Key Market Challenges

Competition from other diagnostic tests

Syndromic testing competes with other diagnostic tests, such as molecular diagnostics and serological diagnostics. These tests may be more accurate and can provide more information about the underlying cause of the syndrome. molecular diagnostics can identify the specific pathogen causing the syndrome, while serological diagnostics can detect the presence of antibodies to the pathogen. This information can be helpful in making a diagnosis and determining the best course of treatment. Healthcare providers may be more accustomed to using traditional diagnostic methods that they are already familiar with, which can lead to a resistance to adopting newer syndromic testing approaches. Diagnostic methods that have a long history of use and established reliability may be favored by healthcare professionals, making it difficult for syndromic testing to gain traction.

Key Market Trends

Rise of Point-of-Care-Testing (POCT)

The rise of Point-of-Care Testing (POCT) is a significant trend in the global Acute Care Syndromic Testing Market. Point-of-Care Testing refers to diagnostic testing performed at or near the patient's location, providing rapid results that can guide immediate clinical decision-making. POCT allows healthcare providers to quickly diagnose and initiate treatment plans, particularly in acute care settings where time is critical. Acute care syndromic testing, when adapted to POCT platforms, enables rapid identification of pathogens responsible for acute symptoms, leading to more timely and appropriate interventions. Syndromic testing conducted at the point of care eliminates the need to send samples to centralized laboratories, reducing turnaround times for results. This speed is essential in managing acute conditions and outbreaks, where rapid decisions are crucial. Point-of-care syndromic testing empowers healthcare providers to make informed decisions at the bedside. Immediate results help guide isolation measures, treatment choices, and patient management strategies, improving overall care. In situations such as infectious disease outbreaks, POCT-based acute care syndromic testing can contribute to rapid containment by quickly identifying cases and implementing appropriate control measures to prevent further spread. POCT helps optimize resource allocation by avoiding unnecessary transfers, repeat tests, and prolonged hospital stays. This efficiency is especially relevant in acute care scenarios where resources may be limited. During events like large gatherings or disaster response, point-of-care syndromic testing can provide rapid screening for infectious diseases, aiding in quick identification and management of potential outbreaks. POCT can be particularly valuable in remote or underserved regions with limited access to central laboratories. Acute care syndromic testing at the point of care bridges the gap in diagnostic capabilities. Real-time Surveillance: Point-of-care syndromic testing generates data that can be analyzed in real time, contributing to disease surveillance efforts, early detection of emerging pathogens, and timely public health responses.

Key Market Players

Abbott Laboratories

Becton, Dickinson and Company

Biocartis NV

bioMerieux SA (BioFire Diagnostics)

Danaher Corporation (Cepheid, Inc.)

DiaSorin S.p.A (Luminex Corporation)

Eurofins Scientific (Eurofins Viracor)

Hologic Inc.

Laboratory Corporation of America Holdings.

QIAGEN N.V.

Report Scope:

In this report, the Global Acute Care Syndromic Testing Markets Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Acute Care Syndromic Testing Market, By Disease Type:

• Respiratory Diseases
• Gastrointestinal Diseases
• Genitourinary Diseases
• Tropical Diseases
• Others

Acute Care Syndromic Testing Market, By Target:

• Bacteria
• Fungi
• Viruses
• Parasites

Acute Care Syndromic Testing Market, By Sample Type:

• Blood
• Urine
• Biofluids
• Stool
• Swabs
• Others

Acute Care Syndromic Testing Market, By End User:

• Hospitals
• Clinical & Diagnostics Laboratories
• Research & Academic Institutions
• Others

Acute Care Syndromic Testing Market, By region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Major companies present in the Global Acute Care Syndromic Testing Market.

Available Customizations:

Global Acute Care Syndromic Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Acute Care Syndromic Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Disease Type (Respiratory Diseases, Gastrointestinal Diseases, Genitourinary Diseases, Tropical Diseases, Others)
  • 5.2.2. By Target (Bacteria, Viruses, Fungi, Parasites)
  • 5.2.3. By Sample Type (Blood, Urine, Biofluids, Stool, Swabs, Others)
  • 5.2.4. By End User (Hospitals, Clinical & Diagnostics Laboratories, Research & Academic Institutions, Others)
  • 5.2.5. By Company (2024)
  • 5.2.6. By Region
• 5.3. Market Map

6. North America Acute Care Syndromic Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease Type
  • 6.2.2. By Target
  • 6.2.3. By Sample Type
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Acute Care Syndromic Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Disease Type
      • 6.3.1.2.2. By Target
      • 6.3.1.2.3. By Sample Type
      • 6.3.1.2.4. By End User
  • 6.3.2. Mexico Acute Care Syndromic Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Disease Type
      • 6.3.2.2.2. By Target
      • 6.3.2.2.3. By Sample Type
      • 6.3.2.2.4. By End User
  • 6.3.3. Canada Acute Care Syndromic Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Disease Type
      • 6.3.3.2.2. By Target
      • 6.3.3.2.3. By Sample Type
      • 6.3.3.2.4. By End User

7. Europe Acute Care Syndromic Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease Type
  • 7.2.2. By Target
  • 7.2.3. By Sample Type
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Acute Care Syndromic Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Disease Type
      • 7.3.1.2.2. By Target
      • 7.3.1.2.3. By Sample Type
      • 7.3.1.2.4. By End User
  • 7.3.2. Germany Acute Care Syndromic Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Disease Type
      • 7.3.2.2.2. By Target
      • 7.3.2.2.3. By Sample Type
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Acute Care Syndromic Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Disease Type
      • 7.3.3.2.2. By Target
      • 7.3.3.2.3. By Sample Type
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Acute Care Syndromic Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Disease Type
      • 7.3.4.2.2. By Target
      • 7.3.4.2.3. By Sample Type
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Acute Care Syndromic Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Disease Type
      • 7.3.5.2.2. By Target
      • 7.3.5.2.3. By Sample Type
      • 7.3.5.2.4. By End User

8. Asia-Pacific Acute Care Syndromic Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease Type
  • 8.2.2. By Target
  • 8.2.3. By Sample Type
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Acute Care Syndromic Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Disease Type
      • 8.3.1.2.2. By Target
      • 8.3.1.2.3. By Sample Type
      • 8.3.1.2.4. By End User
  • 8.3.2. India Acute Care Syndromic Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Disease Type
      • 8.3.2.2.2. By Target
      • 8.3.2.2.3. By Sample Type
      • 8.3.2.2.4. By End User
  • 8.3.3. South Korea Acute Care Syndromic Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Disease Type
      • 8.3.3.2.2. By Target
      • 8.3.3.2.3. By Sample Type
      • 8.3.3.2.4. By End User
  • 8.3.4. Japan Acute Care Syndromic Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Disease Type
      • 8.3.4.2.2. By Target
      • 8.3.4.2.3. By Sample Type
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Acute Care Syndromic Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Disease Type
      • 8.3.5.2.2. By Target
      • 8.3.5.2.3. By Sample Type
      • 8.3.5.2.4. By End User

9. South America Acute Care Syndromic Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease Type
  • 9.2.2. By Target
  • 9.2.3. By Sample Type
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Acute Care Syndromic Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Disease Type
      • 9.3.1.2.2. By Target
      • 9.3.1.2.3. By Sample Type
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Acute Care Syndromic Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Disease Type
      • 9.3.2.2.2. By Target
      • 9.3.2.2.3. By Sample Type
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Acute Care Syndromic Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Disease Type
      • 9.3.3.2.2. By Target
      • 9.3.3.2.3. By Sample Type
      • 9.3.3.2.4. By End User

10. Middle East and Africa Acute Care Syndromic Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Disease Type
  • 10.2.2. By Target
  • 10.2.3. By Sample Type
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Acute Care Syndromic Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Disease Type
      • 10.3.1.2.2. By Target
      • 10.3.1.2.3. By Sample Type
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Acute Care Syndromic Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Disease Type
      • 10.3.2.2.2. By Target
      • 10.3.2.2.3. By Sample Type
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Acute Care Syndromic Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Disease Type
      • 10.3.3.2.2. By Target
      • 10.3.3.2.3. By Sample Type
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Abbott Laboratories
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Becton, Dickinson and Company
• 15.3. Biocartis NV
• 15.4. bioMerieux SA (BioFire Diagnostics)
• 15.5. Danaher Corporation (Cepheid, Inc.)
• 15.6. DiaSorin S.p.A (Luminex Corporation)
• 15.7. Eurofins Scientific (Eurofins Viracor)
• 15.8. Hologic Inc.
• 15.9. Laboratory Corporation of America Holdings.
• 15.10. QIAGEN N.V.

16. Strategic Recommendations

17. About Us & Disclaimer